Bristol-Myers Squibb Company ((BMY)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Study Overview: Bristol-Myers Squibb Company is conducting a study titled ‘A Phase 3b/4 Multi-center, Randomized, Open-label, Long-term Safety Study of Deucravacitinib in Comparison to Ustekinumab in Participants With Moderate-to-Severe Plaque Psoriasis.’ The study aims to evaluate the long-term safety of the drug Deucravacitinib compared to Ustekinumab in individuals with psoriasis, a significant step in understanding treatment options for this condition.
Intervention/Treatment: The study tests two drugs: Deucravacitinib, an experimental treatment, and Ustekinumab, an active comparator. Both are administered in specified doses to assess their safety profiles in treating moderate-to-severe plaque psoriasis.
Study Design: This interventional study is randomized with a parallel assignment model. It is open-label, meaning no masking is involved, and its primary purpose is treatment-focused, aiming to compare the long-term safety of the two drugs.
Study Timeline: The study is not yet recruiting, with an estimated start date of October 30, 2025. The initial submission was on August 4, 2025, and the last update was submitted on August 13, 2025. These dates are crucial for tracking the study’s progress and planning for future developments.
Market Implications: The study could influence Bristol-Myers Squibb’s stock performance by potentially expanding its treatment portfolio for psoriasis, a competitive market with significant demand. Positive outcomes might boost investor confidence and position the company favorably against competitors in the dermatological treatment space.
The study is ongoing, with further details available on the ClinicalTrials portal.